Sientra Inc (SIEN.OQ)

About

Sientra, Inc. is a medical aesthetics company. The Company's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	--
Market Cap(Mil.):	$307.56
Shares Outstanding(Mil.):	19.31
Dividend:	--
Yield (%):	--

Financials

	SIEN.OQ	Industry	Sector
P/E (TTM):	--	32.29	32.76
EPS (TTM):	-2.66	--	--
ROI:	-61.89	13.92	14.61
ROE:	-64.43	16.77	16.33

Latest News about SIEN.OQ

BRIEF-Sientra Q1 Loss Per Share $0.99

* Q1 EARNINGS PER SHARE VIEW $-0.84 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-Sientra Inc. Announces Closing Of $115 Mln Public Offering Of Common Stock

* SIENTRA, INC. ANNOUNCES CLOSING OF $115 MILLION PUBLIC OFFERING OF COMMON STOCK AND EXERCISE IN FULL OF UNDERWRITERS’ OVER-ALLOTMENT OPTION Source text for Eikon: Further company coverage:

07 May 2018

BRIEF-Sientra Announces Pricing Of Upsized Public Offering Of Common Stock

* SIENTRA ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK

03 May 2018

BRIEF-Sientra Inc Says Commenced Underwritten Public Follow-On Offering Of About $75 Mln Of Its Stock To Be Sold By Co

* SIENTRA INC - COMMENCED UNDERWRITTEN PUBLIC FOLLOW-ON OFFERING OF ABOUT $75 MILLION OF ITS STOCK TO BE SOLD BY COMPANY

30 Apr 2018

BRIEF-Sientra Sees Preliminary Unaudited Net Sales For Q1 2018 Of About $14.5 Mln

* SIENTRA INC - SEES PRELIMINARY UNAUDITED NET SALES FOR Q1 2018 OF ABOUT $14.5 MILLION

25 Apr 2018

BRIEF-Sientra Receives FDA Approval Of PMA Supplement

* SIENTRA INC - ADDITIONAL $10 MILLION OF EXISTING CREDIT FACILITY NOW ACCESSIBLE WITH FDA APPROVAL

18 Apr 2018

BRIEF-Sientra Says Reached An Agreement-In-Principle With Staff Of Division Of Enforcement Of U.S. SEC

* SIENTRA INC - REACHED AN AGREEMENT-IN-PRINCIPLE WITH STAFF OF DIVISION OF ENFORCEMENT OF U.S. SECURITIES AND EXCHANGE COMMISSION - SEC FILING

26 Mar 2018

BRIEF-Sientra Reports Qtrly Loss Per Share $0.92

* SIENTRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

13 Mar 2018

BRIEF-Sientra Says Co Enters Into Agreement With Stifel, Nicolaus & Co Inc

* SIENTRA SAYS CO ENTERED INTO AGREEMENT WITH STIFEL, NICOLAUS & CO INC, TO SELL SHARES OF STOCK HAVING AN OFFERING PRICE OF UP TO $50 MILLION- SEC FILING Source text for Eikon: Further company coverage:

20 Feb 2018

» More SIEN.OQ News

Competitors

	Price	Chg
Allergan plc (AGN.N)	$183.50	-0.98
Johnson & Johnson (JNJ.N)	$131.68	+1.25